#ESMO26 最令人期待的摘要之一：NataLEE 试验的 OS 结果
辅助治疗 ribociclib 可带来具有统计学显著性的 ⬆️ OS：60 个月时差异为 1.2%，72 个月（6 年）时差异为 2.1%
IDFS、DDFS 和 DRFS 的获益均得到确认并持续存在
@OncoAlert
996 浏览 · 25 赞 · 11 转发 · 3 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- Gabriel Lazcano@gv_lazcano
@ElisaAgostinett @OncoAlert Pharma can't continue to offer expensive treatments with marginal benefits and expect nations to just go with it. We need to be more socially responsible too.
- Gabriel Lazcano@gv_lazcano
@ElisaAgostinett @OncoAlert This needs better patient selection. As a one size fits all, I don't think most healthcare systems would have a good time covering this. We recently added pembro for TN and the national budget has been consequently severely strained.
- Elisa Agostinetto@ElisaAgostinett
Simultaneous publication in @Annals_Oncology ‼️ https://www.annalsofoncology.org/article/S0923-7534(26)08640-0/fulltext @OncoAlert @myESMO
来源：Elisa Agostinetto · x.com